Effects of the cynanchum wilfordii ethanol extract on the serum lipid profile in hypercholesterolemic rats

Preventive Nutrition and Food Science

Volumn 18, Issue 3, 2013, Pages 157-162

  Lee, Hye Sung ^a   Choi, Jun Hyeok ^b   Kim, Young Eon ^c   Kim, In Ho ^c   Kim, Byoung Mok ^c   Lee, Chang Ho ^c  

^a Kyung Hee University   (South Korea)

^b Keimyung University   (South Korea)

^c Korea Food Research Institute   (South Korea)

Author keywords

Atherogenic index; Cynanchum wilfordii; HDL cholesterol; Hypercholesterolemia; LDL cholesterol

Indexed keywords

EID: 84887234374     PISSN: 22871098     EISSN: 22878602     Source Type: Journal    
DOI: 10.3746/pnf.2013.18.3.157     Document Type: Article

References (35)

1. Ahmed F, Waslien C, Al-Sumaie M. 2012. Trends and risk factors of hypercholesterolemia among Kuwaiti adults: National nutrition surveillance data from 1998 to 2009. Nutrition 28: 917-923.
2. Basu S, McKee M, Galea G, Stuckler D. 2013. Relationship of soft drink consumption to global overweight, obesity, and diabetes: A Cross-National Analysis of 75 Countries. Am J public health doi: 10.2105/AJPH.2012.300974.
3. KCDC. 2010. Korea national health and nutrition examination survey (KNHANES V-1). Korea centers for disease control and prevention, Chungcheongbuk-do, Korea.
4. Sang CJ, Yong TJ, Byung KY, Rezuanul I, Sundar RK, Gerald P, Kai YC, Chi HS. 2009. White button mushroom (Agarieus bisporus) lowers blood glucose and cholesterol levels in diabetic and hypercholesterolemic rats. Nutr Res 30: 49-56.
5. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. 1994. Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European society of cardiology, European atherosclerosis society and European society of hypertension. Eur Heart J 15: 1300-1331.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, lorimer R, Macfariane PW, McKoillop JH, Packard CJ. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1308.
8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.
9. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 291: 1071-1080.
10. Hodel C. 2002. Myopathy and rhabdomyolysis with lipidlowering drugs. Toxicol Lett 128: 159-168.
11. Moosmann B, Behl C. 2004. Selenoprotein synthesis and side-effects of statins. Lancet 363: 892-894.
12. Jeppesen U, Gaist D, Smith T, Sindrup SH. 1999. Statins and peripheral neuropathy. Eur J Clin Pharmacol 54: 835-838.
13. Omar MA, Wilson JP. 2002. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36: 288-295.
14. Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. 1995. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 58: 625-628.
15. Chong PH, Boskovich A, Stevkovic N, Bartt RE. 2004. Statin-associated peripheral neuropathy: Review of the literature. Pharmacotherapy 24: 1194-1203.
16. Baker SK, Tarnopolsky MA. 2001. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 24: 258-272.
17. Shan L, Jiu RH, Shen YH, Zhang WD, Zhang C, Wu DZ, Su J, Xu XK. 2006. Gastroprotective effect of a traditional Chinese herbal drug "Baishouwu" on experimental gastric lesions in rats. J Ethnopharmacol 3: 389-394.
18. Kim HS. 2004. Effects of Cynanchum wilfordii extract on serum lipid components and enzyme activities in hyperlipidemic and streptozotocin-induced diabetic rats. Korean J of Human Ecology 7: 1-11.
19. Choi DH, Lee YJ, Kim EJ, Li X, Kim HY, Hwang SM, Yoon JJ, Lee SM, Min EK, Kang DG, Lee HS. 2010. Ethanol extract of Cynanchum wilfordii produces endothelium-dependent relaxation in rat aorta and anti-inflammatory activity in human aortic smooth muscle cells. Journal of Korean Oriental Medicine 31: 45-57.
20. Yoon MY, Choi NH, Min BS, Choi GJ, Choi YH, Jang KS, Han SS, Cha BC, Kim JC. 2011. Potent in vivo antifungal activity against powdery mildews of pregnane glycosides from the roots of Cynanchum wilfordii. J Agric Food Chem 59: 12210-12216.
21. Reeves PG, Nielsen FG, Fahey GC Jr. 1993. AIN-93 purified diets for laboratory rodents: final report of the American institute of nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123: 1939-1951.
22. Anderson JW, Jones AE, Riddel-Mason S. 1994. Ten different dietary fibers have significantly different effects on serum and liver lipids of cholesterol-fed rats. J Nutr 124: 78-83.
23. Kim HS. 2004. Effects of Cynanchum wilfordii extract on serum lipid components and enzyme activities in hyperlipidemic and streptozotocin-induced diabetic rats. Korean J Human Ecology 7: 1-11.
24. Kannel WB. 2000. The Framingham study: Its 50-year legacy and future promise. J Atheroscler Thromb 6: 60-66.
25. Tapsell LC, Gillen LJ, Patch CS, Batterham M, Owen A, Baré M, Kennedy M. 2004. Including walnuts in low-fat/ modified-fat improves HDL-cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes Care 12: 2777-2783.
26. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. 2007. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Eng J Med 357: 1301-1310.
27. Scandinaviasn Simvastin Survival Study Group. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
28. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279: 1615-1622.
29. Whitney E, Rolfes SR. 2005. Understanding nutrition. 10th ed. Thomson Wadsworth, Belmont, CA, USA. p 622-623.
30. Assmann G, Schulte H, Eckardstein AV, Huang Y. 1996. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124: S11-S20.
31. Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, Tall AR. 2004. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 45: 948-953.
32. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. 1977. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 62: 707-714.
33. Sharret AR, Ballabtyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Oatsch W. 2001. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104: 1108-1113.
34. Chapman MJ. 2006. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Therapeut 111: 893-908.
35. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. 1986. Incidence of coronary heart disease and lipoprotein cholesterol Levels. The Framingham Study. JAMA 256: 2835-2838.